Live Chat

CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 76,3% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Gilead GILD

Gilead live grafieken

Inzichten

Weekly Search
Weekly
Daily
date Sluit change % verandering Openen Piek Bodem

Markets.com news

New Zealand dollar drops on unexpected dovish tone from RBNZ
Georgy Istigechev 2024 Jul 10, 10:00

Unexpected dovish tone from RBNZ drops New Zealand dollar

Forex Indices USD
Sterling steady as investors take in UK, French election results
Georgy Istigechev 2024 Jul 09, 10:15

Sterling steady near one-month high in wake of UK election

Forex Indices GBP USD EUR
BP shares fall on Q2 profit warning
Georgy Istigechev 2024 Jul 09, 10:00

BP shares drop over 4% on Q2 lower profit warning

Shares Indices Oil FTSE100
BP shares dip ahead of Powell Congress testimony
Neil Wilson 2024 Jul 09, 07:30

BP dips, Powell Congress speech ahead, records for Tokyo, NY

Shares Indices Forex Commodities

Info

Spread

0.62

Spread (%)

0.6757 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Dinsdag

14:31 - 20:59

Maandag

14:31-20:59

Woensdag

14:31-20:59

Donderdag

14:31-20:59

Vrijdag

14:31-20:59

Inkomstenverklaring

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

116401618944

Uitstaande aandelen

1246269952

Datum winstcijfer (volgende)

2013-01-28

instr__dividend_date

2024-12-30

instr__ex_dividend_date

2024-12-13

instr__forward_annual_dividend_rate

3.08

instr__forward_annual_dividend_yield

0.0333

Winst per aandeel

0.09

Uitstaande aandelen

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Meer informatie over dit instrument

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten
Trustpilot
Live Chat